Kourea H P, Koutras A K, Scopa C D, Marangos M N, Tzoracoeleftherakis E, Koukouras D, Kalofonos H P
Department of Pathology, University Hospital of Patras, Patras Medical School, Patras, Rion 26500, Greece.
Mol Pathol. 2003 Dec;56(6):328-35. doi: 10.1136/mp.56.6.328.
To look for correlations between expression of cell cycle regulatory proteins p34(cdc2), p21(WAF1), and p53 in node negative invasive ductal breast carcinoma, or between these proteins and clinicopathological parameters, and to assess their prognostic value.
Immunohistochemistry using formalin fixed, paraffin wax embedded sections from 94 breast carcinomas. Adjacent benign epithelial breast tissue was available in 74 cases. Median follow up was 72 months.
Nuclear and cytoplasmic p34(cdc2) expression was seen in 80 and 62 tumours, respectively; nuclear expression was seen in adjacent benign epithelium in 12 cases. p21(WAF1) and p53 were positive in 48 and 21 tumours, respectively. High expression of p34(cdc2) in neoplastic nuclei was associated with higher histological grade and p53 expression, but not with tumour size, steroid receptor status, patient age, menopausal status, recurrence, metastasis, disease free survival (DFS), or overall survival (OS). p34(cdc2) in tumour cytoplasm was associated with p34(cdc2) nuclear positivity, high tumour grade, and DFS in univariate but not multivariate analysis. In contrast, p34(cdc2) expression in benign tissue independently predicted DFS and OS in univariate and multivariate analysis. Expression of p53 was associated with high tumour grade and negative steroid receptors, but not with recurrence, metastasis, DFS, or OS. p21(WAF1) expression was not associated with the examined parameters.
p34(cdc2), p21(WAF1), and p53 expression does not predict outcome in node negative breast carcinoma, although p34(cdc2) expression in benign tissue is related to prognosis. The association between p34(cdc2) and p53 implicates p53 in G2-M cell cycle checkpoint control, possibly via mediators unrelated to p21(WAF1).
寻找p34(cdc2)、p21(WAF1)和p53等细胞周期调节蛋白在淋巴结阴性浸润性导管癌中的表达之间,或这些蛋白与临床病理参数之间的相关性,并评估其预后价值。
对94例乳腺癌的福尔马林固定、石蜡包埋切片进行免疫组织化学检测。74例患者有相邻的乳腺良性上皮组织。中位随访时间为72个月。
分别在80例和62例肿瘤中观察到核和细胞质p34(cdc2)表达;12例相邻良性上皮中可见核表达。p21(WAF1)和p53分别在48例和21例肿瘤中呈阳性。肿瘤细胞核中p34(cdc2)的高表达与更高的组织学分级和p53表达相关,但与肿瘤大小、类固醇受体状态、患者年龄、绝经状态、复发、转移、无病生存期(DFS)或总生存期(OS)无关。肿瘤细胞质中的p34(cdc2)在单因素分析中与p34(cdc2)核阳性、高肿瘤分级和DFS相关,但在多因素分析中无关。相比之下,良性组织中p34(cdc2)的表达在单因素和多因素分析中均独立预测DFS和OS。p53的表达与高肿瘤分级和类固醇受体阴性相关,但与复发、转移、DFS或OS无关。p21(WAF1)的表达与所检测的参数无关。
p34(cdc2)、p21(WAF1)和p53的表达不能预测淋巴结阴性乳腺癌的预后,尽管良性组织中p34(cdc2)的表达与预后相关。p34(cdc2)和p53之间的关联表明p53可能通过与p21(WAF1)无关的介质参与G2-M细胞周期检查点控制。